Navigation Links
ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Date:10/10/2007

a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the Company's web site at http://www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that results from ADVENTRX's on-going marketing-enabling study will not indicate bioequivalence of ANX-530 and Navelbine; the FDA's views on the appropriateness of seeking marketing approval of ANX-530 under Section 505(b)(2); difficulties or delays in manufacturing, marketing and obtaining regulatory approval for ANX-530, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-530 and other challenges by patent holders during the Section 505(b)(2) process; uncertainty under Section 505(b)(2) resulting from legal action against the FDA and the potential that future interpretations of Section 505(b)(2) could delay or prevent the FDA from approving any Section 505(b)(2) NDA; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; patent and non-patent exclusivity covering Navelbine; ADVENTRX's lack of lo
'/>"/>

SOURCE ADVENTRX Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
2. Adventrx Announces Positive Data From Multidrug Therapy With CoFactor
3. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Dr. Michael Gabriel of a prominent ... recent study, which shows how grief in pregnancy may cause ... According to US News , "Unborn ... than others to grow up overweight or obese, even if ... two specific types of stress that caused obesity: "Children whose ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)...  IRIDEX Corporation (NASDAQ: IRIX ) today ... financial results after the market closes on Thursday, ... the Company will host a conference call with the ... Thursday, July 31, 2014 to discuss ... Interested parties may access the live conference ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/26/2014)... (PRWEB) July 26, 2014 ... recently updated by Vkool.com, this is a ... safe methods for treating all types of ...     Tinnitus due to Ménière's ... ,     Nerve pathway tinnitus , ...
(Date:7/26/2014)... Columbus, OH (PRWEB) July 26, 2014 The ... medical guidelines list that includes a new medication guide for ... as a serious side-effect of taking the topical low testosterone ... notes that AbbVie Inc., the makers of the low testosterone ... include symptoms of pain, swelling or redness as signs of ...
(Date:7/26/2014)... Wa (PRWEB) July 26, 2014 According ... updated by Vkool.com, this is a comprehensive guide that ... unwanted tattoos . This book also teaches them ... imitate common medical procedures in their own home for ... that "Get Rid Tattoo Naturally" book includes step-by-step tutorials ...
(Date:7/25/2014)... Texas (PRWEB) July 26, 2014 ... and China Gel Permeation Chromatography Industry” is ... the Global and China Gel Permeation Chromatography ... Chromatography information, including Gel Permeation Chromatography definition, ... well as industry overview. This research covers ...
(Date:7/25/2014)... July 25, 2014 A federal judge ... in two DePuy Pinnacle hip lawsuits ( http://www.depuypinnacle-lawsuit.com/ ... the claims to go before a jury on September ... rendered on July 18th, U.S. District Judge Ed Kinkeade ... two Plaintiffs’ claims may proceed to trial against Johnson ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4
... -- People with heart conditions who take vitamins may be ... according to a new study. Researchers from the Intermountain ... heartbeat -- known as atrial fibrillation -- what they knew ... were also asked how well they followed their prescription for ...
... Healthy, new heart cells have been generated by animals ... derived from cardiac biopsies or "cardiospheres," according to research ... and Biomedical Sciences. , The research is being ... the American Heart Association in Orlando. , The UB ...
... which can develop into any cell type in the ... drive their metabolic activities. In contrast, mature ... mitochondria to convert sugar and oxygen into carbon dioxide ... phosphorylation for their metabolic needs. How cells ...
... surgical techniques on toy animals before having to perform operations ... the same time, the use of laboratory animals is minimised. ... - the Faculty of Life Sciences at the University of ... the ,teddy laboratory, strengthens learning and the teaching environment. ...
... -- Preliminary trials indicate that a new drug designed ... shows considerable promise, both on its own and in ... is part of a class of so-called "cholesteryl ester ... CETP medication to undergo testing as a means to ...
... Reinberg HealthDay Reporter , TUESDAY, Nov. 15 (HealthDay ... the statin drug Zocor (simvastatin) to help lower their cholesterol ... Even though niacin appeared to increase HDL cholesterol -- the ... in the blood, it did not reduce the risk of ...
Cached Medicine News:Health News:Heart Patients Using Vitamins May Take Meds Improperly 2Health News:Heart Patients Using Vitamins May Take Meds Improperly 3Health News:New heart cells increase by 30 percent after stem cell infusion 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 3Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 4Health News:Surgery on toy animals lessens anxiety of veterinary students 2Health News:Cholesterol Drug Shows Promise in Early Research 2Health News:Cholesterol Drug Shows Promise in Early Research 3Health News:No Benefit From Niacin for Heart Patients in Study 2Health News:No Benefit From Niacin for Heart Patients in Study 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 19.0 mm and length 21 mm....
... The BacT/Alert 3D Select ... art, automated microbial detection system ... fluid and mycobacteria culturing. This ... data management or laboratory information ...
IDS Rapid ANA II System, a microbial identification system....
IDS Rapid One, a microbial identification system....
Medicine Products: